Search results for "Remission"

showing 10 items of 213 documents

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

2008

1. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Epub 2008 Mar 14. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M. Divisione di Gastroenterologia, Azienda Ospedaliera V. Cervello, Palermo, Italy. fabiotinemd@virgilio.it BACKGROUND: Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn's disease (CD). AIM: To explain variation of remission and response rates in active luminal CD. METHODS: We studied control patients from trials of biological therapies through articles retriev…

AdultBiological TherapyMalePlacebosTreatment Outcomemetanalysis. biologics.crohn's diseaseCrohn DiseaseDose-Response Relationship DrugRemission InductionHumansFemaleRandomized Controlled Trials as Topic
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

Spontaneous Resolution of Delayed Suprachoroidal Hemorrhage in the Single Eye Following Needling in Congenital Glaucoma

2017

Suprachoroidal hemorrhage (SCH) is a rare, but potentially vision-threatening event with poor long-term visual prognosis. At present, there is disagreement whether surgical intervention or conservative treatment is superior in the management. We report on a case of spontaneous resolution of severe SCH after needling procedure in the only eye of a young patient with congenital glaucoma.A 43-year-old woman with congenital glaucoma was scheduled for bleb needling in her only eye. Preoperative best-corrected visual acuity was 20/40 and intraocular pressure 20 mm Hg. On the third postoperative day, she developed a massive delayed SCH with appositional (kissing) choroidal bullae and visual acuity…

AdultChoroid Hemorrhagemedicine.medical_specialtyCongenital glaucomagenetic structuresRemission SpontaneousVisual AcuityGlaucomaSuprachoroidal hemorrhagePostoperative Hemorrhage03 medical and health sciences0302 clinical medicineOphthalmologyHumansMedicineIntraocular PressureDry needlingbusiness.industryGlaucomamedicine.diseaseConservative treatmentOphthalmology030221 ophthalmology & optometryDrainageFemalebusinessSclera030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

HLA-DRB1*1301 AND *1302 protect against chronic hepatitis B

1997

Abstract Background/Aims: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. Methods: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were d…

AdultHepatitis B virusRemission SpontaneousPopulationEnzyme-Linked Immunosorbent AssayMajor histocompatibility complexmedicine.disease_causePolymerase Chain ReactionHLA-DQ alpha-ChainsVirusHLA-DQ AntigensMHC class ImedicineHumansSerologic TestsProspective StudiesHepatitis B AntibodieseducationHLA-DRB1AllelesHepatitis B viruseducation.field_of_studyMHC class IIHepatitis B Surface AntigensHepatologybiologyHLA-DR AntigensHepatitis BVirologyChronic infectionImmunoglobulin GChronic DiseaseDNA ViralImmunologybiology.proteinHLA-DRB1 ChainsJournal of Hepatology
researchProduct

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

2016

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabKaplan-Meier Estimatemedicine.disease_causeGastroenterologyDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedShrinkageCetuximabbusiness.industryRemission InductionTumor shrinkageMiddle Agedmedicine.diseaseBevacizumabTreatment Outcome030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilKRASColorectal Neoplasmsbusinessmedicine.drugInternational Journal of Cancer
researchProduct

A Phase I Study of Cisplatinum plus 5-Fluorouracil in Modulation with Citrovorum Factor in Metastatic Colorectal Carcinoma

1991

A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil. The first group of patients received cisplatin at the dose of 5 mg/m2/week. Cisplatin was then escalated to 10, 15, 20, 25, 30, and 35 mg/m2/week for subsequent groups of patients. Gastrointestinal side-effects were the dose-limiting toxicity. A therapy related death was seen at the dose of 35 mg/m2/week of cisplatin. The maximally tolerated dose of cisplatin in combination with 5-fluorouracil and citrovorum factor is 20 mg/m2/week. The…

AdultMale0301 basic medicinemedicine.medical_specialtyColorectal cancer030106 microbiologyLeucovorinPhases of clinical researchRectumGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedPharmacologyCisplatinbusiness.industryCarcinomaRemission InductionMiddle Agedmedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracil030220 oncology & carcinogenesisToxicityDrug EvaluationFemaleFluorouracilCisplatinColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck

1995

Despite considerable progress achieved in the management of head and neck carcinomas (HNC) in the last decade, the prognosis of patients with advanced squamous cell HNC is still dismal. On the basis of the reported good activity of a new vinca alkaloid derivative, i.e., vinorelbine (VNR), we tested the combination of cisplatin and VNR in a series of patients with recurrent or previously untreated unresectable squamous cell HNC. Thirty-five patients with recurrent or previously untreated unresectable squamous cell HNC were treated with a combination of cisplatin 80 mg/m2 on day 1, plus vinorelbine 25 mg/m2 i.v. push on days 1 and 8. This cycle was repeated every 3 weeks. Analysis of response…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentVinblastineVinorelbineGastroenterologyDrug Administration ScheduleVinca alkaloidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCisplatinChemotherapybusiness.industryRemission InductionVinorelbineMiddle AgedVinblastineSurgeryRadiation therapyRegimenOncologyHead and Neck NeoplasmsCarcinoma Squamous CellVomitingFemaleCisplatinNeoplasm Recurrence Localmedicine.symptombusinessmedicine.drug
researchProduct